SCHEDULE: T. Rowe Price Discloses 15.3% Stake in Shattuck Labs

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting a beneficial ownership of 15.3% in Shattuck Labs Inc. common stock as of June 30, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, reporting its beneficial ownership of Shattuck Labs Inc. common stock.
• As of June 30, 2026, the firm holds 13,432,540 shares, representing 15.3% of the class of securities.
• This filing indicates a significant institutional investment in Shattuck Labs Inc.
• The filing is an amendment, suggesting a previous filing or a change in holdings or reporting status.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but stable institutional holding without immediate aggressive action.

Positives

• Significant institutional ownership by a reputable investment firm (T. Rowe Price) can signal confidence in the company's long-term prospects.
• The 15.3% stake indicates a substantial commitment to Shattuck Labs Inc.

Negatives

• The filing itself does not contain negative financial or operational information about Shattuck Labs Inc.; it solely reports ownership.

Risks

• Potential for future changes in T. Rowe Price's holdings, which could impact share price if significant selling occurs.
• Concentration of ownership with a single large institutional investor could lead to volatility if that investor changes its strategy.

Future Outlook

This filing is primarily an ownership disclosure and does not contain forward-looking statements or guidance from Shattuck Labs Inc. itself. The future outlook is indirectly influenced by the continued investment from T. Rowe Price.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant institutional filings like this are common in the biotechnology and pharmaceutical sectors, where long-term investment horizons are typical. T. Rowe Price is a major institutional investor known for its active management and research-driven approach.

Comparison to Industry Standards

• Institutional ownership percentages vary widely by industry and company stage. For a publicly traded biotech company, a 15.3% stake by a single large asset manager like T. Rowe Price is substantial and suggests a strong conviction in the company's potential, aligning with typical benchmarks for significant institutional backing in the sector.

Stakeholder Impact

• Shareholders: May view the significant stake by T. Rowe Price as a positive endorsement, potentially increasing investor confidence. However, it also means a large portion of the company is held by one entity, which could influence market dynamics.
• Management: The presence of a large institutional investor may lead to increased scrutiny and engagement on corporate strategy and performance.
• Creditors/Suppliers: Indirectly impacted by the company's stability and perceived value, which can be influenced by major shareholder actions.

Next Steps

• Monitoring T. Rowe Price's future filings for any changes in their beneficial ownership of Shattuck Labs Inc. stock.
• Observing Shattuck Labs Inc.'s operational and financial performance to understand the underlying reasons for T. Rowe Price's investment.

Key Dates

Recommendation

This filing is a Schedule 13G, which primarily reports institutional ownership and does not contain operational or financial results that would warrant a buy or sell recommendation. The significant stake by T. Rowe Price suggests a long-term investment perspective, making 'hold' appropriate as it indicates stability and institutional confidence without immediate catalysts for a significant price movement.

Keywords

Shattuck Labs, T. Rowe Price, Schedule 13G, Institutional Ownership, Beneficial Ownership, Common Stock, Investment Management